
==== Front
Surg Neurol Int
Surg Neurol Int
Surgical Neurology International
2229-5097
2152-7806
Scientific Scholar USA

10.25259/SNI_431_2024
10.25259/SNI_431_2024
Case Report
Small-cell neuroendocrine carcinoma of the cervix with leptomeningeal spread: A rare coincidence report and literature review
Azab Mohammed A. 1mohammed.azab@kasralainy.edu.eg

Atallah Oday 2oday.atallah@yahoo.de

El-Gohary Nour 3elgohary.nono@gmail.com

Hazim Ahmed 1ahmedabulnasr@gmail.com

Mostafa Hamed Abdelma’aboud 4hamid.12muhmd@gmail.com

1 Department of Neurosurgery, Cairo University Hospital, Cairo, Egypt
2 Department of Neurosurgery, Hannover Medical School, Hannover Medical School, Hannover, Germany
3 Department of Neurology, Cairo University Hospital, Cairo, Egypt
4 Department of Neurosurgery, Hamed Abdelma’aboud Mostafa, AlAzher University, Dameitta, Egypt
* Corresponding author: Mohammed A. Azab, Department of Neurosurgery, Cairo University Hospital, Cairo, Egypt. mohammed.azab@kasralainy.edu.eg
2024
30 8 2024
15 31005 6 2024
06 8 2024
Copyright: © 2024 Surgical Neurology International
2024
https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Background:

Metastasis from cancers of the cervix to the central nervous system is relatively uncommon. Small-cell neuroendocrine cancer of the cervix is a very rare tumor with a high tendency to spread early.

Case Description:

A 33-year-old-woman was diagnosed with a small-cell neuroendocrine cancer of the cervix after complaining about a long time of post-coital bleeding. The patient was treated with eight cycles of chemotherapy and whole pelvis consolidation radiotherapy. One year later, the patient experienced local recurrence with metastases to the liver, left adrenal, and brain. Brain metastases were treated with radiosurgery. The patient started immunotherapy. Two months later, the patient was presented to the emergency department with urinary incontinence, neck pain, and difficulty walking. She was then diagnosed with craniospinal leptomeningeal disease (LMD). The patient received craniospinal palliative radiation therapy. The disease activity was severely progressive, and the patient passed out within 10 days after being diagnosed with cranial LMD.

Conclusion:

A high index of suspicion for LMD is essential in patients diagnosed with cervix cancer who present with unexplained neurologic symptoms, especially with the high-grade neuroendocrine cancer type. Implementing robust research to uncover the biology of these aggressive tumors is important due to the rarity of this pathology.

Cervix
Leptomeningeal disease
Metastasis
Neuroendocrine cell cancer
==== Body
pmc

INTRODUCTION

Leptomeningeal disease (LMD) is characterized by diffuse multifocal involvement of the meninges by cancerous cells. It is considered a lethal complication of malignancy. Cancers that are associated with a high incidence of LMD include melanoma, lymphoma, leukemia, and lung and breast cancer.[1,2,4,19] Recently, the prolonged survival of patients diagnosed with cancer resulted in an increased incidence of LMD.[18,24]

Recently, cervical cancer incidence has declined due to the widespread Human papilloma virus (HPV) vaccinations and the regular screening.[6] Neuroendocrine tumors arise from the embryonic neuroectodermal origin and frequently occur in the gastrointestinal tract, pancreas, and lung.[13] Neuroendocrine tumors of the cervix represent about 0.9– 1.5% of all cervical cancers, and the small-cell variant is the most common.[28] They are associated with HPV infection and have a characteristic poor prognosis with early distant spread.[26] The limited incidence of these types of tumors makes diagnosis and treatment difficult and complicated. Brain metastases from primary cervical cancer are relatively uncommon, with an approximate estimate of 0.4– 2%.[25] The incidence of LMD with primary cervical cancer is not yet reported in the literature. In this case report, we describe high-grade neuroendocrine cell cancer (NECC) metastasizing to the brain with leptomeningeal spread and discuss prognosis and the available treatment paradigms.

CASE DESCRIPTION

A 33-year-old woman was referred to a gynecological examination on June 8, 2018, due to repeated episodes of postcoital bleeding and pelvic pain. A mass lesion was detected on magnetic resonance imaging (MRI) in the cervix and upper third of the vagina and measured about 3.8 × 2.7 (AP diameter) × 3.6 (craniocaudal) [Figure 1]. Parametrium and pelvic walls were normal. Biopsy revealed an invasive high-grade neuroendocrine carcinoma, most consistent with small-cell type [Figure 2]. Immunohistochemistry revealed positive staining for synaptophysin and cytokeratin.

Figure 1: T2 magnetic resonance imaging with contrast of the pelvis showing a lesion in the cervix 3.8 × 2.7 (AP diameter) × 3.6 (craniocaudal). Yellow bar is a measurement tool.

Figure 2: Hematoxylin and eosin-stained section of a biopsy from the uterine cervix showing rosette aggregates of uniform small cells with indistinct cell borders, hyperchromatic nuclei with granular chromatin.

The patient was treated with chemotherapy in the form of eight cycles of carboplatin, etoposide, and whole pelvis consolidation radiotherapy with a dose of 4500 cGy in 25 fx, and then he received brachytherapy to the cervix and parametrium with a dose of 1400 cGy in 2 fx. One year later, the patient had a recurrence with multiple metastases affecting the liver, adrenal gland, and brain. The brain metastases were treated with Gamma Knife radiosurgery [Figure 3]. The patient then started immunotherapy in the form of ipilimumab/nivolumab.

Figure 3: A posterior fossa metastatic lesion abutting the brainstem and treated with radiosurgery. The yellow line is the isodose line, the red circles are the individual treatment shots, the green line is the 90% hot spot.

Two months later, she presented to the emergency department with neck stiffness, cervical pain, trouble walking, and bilateral lower limb numbness associated with urinary incontinence. The patient had a Glasgow coma scale (GCS) of 15. Neurologic examination was positive only for cervical pain limitation. MRI spine revealed leptomeningeal enhancement extending from T2 superiorly through the conus medullaris and involving the cauda equina nerve roots [Figure 4]. The patient then received spine radiotherapy (20 Gy in 5 fx). One month later, she presented with lower extremity weakness, dysphagia, dysarthria, and ptosis. By this time, the patient had a GCS of 15. Neurological examination showed weak gag reflex facial nerve weakness H/B grade IV. The presentation was concerning for progressive LMD likely affecting the brainstem and cranial nerves. The patient then received palliative whole brain radiation therapy (WBRT) in the form of 20 Gy/5 fractions. One week later, the patient was admitted with altered mental status. The patient was then transferred to a hospice and passed out due to aspiration and possible respiratory failure after 10 days.

Figure 4: (a) Lumbar spine magnetic resonance imaging (MRI) T2 showing leptomeningeal enhancement along the conus and innumerable tiny nodular enhancing foci along the descending cauda equina nerve roots. (b) Thoracic spine MRI T2 with contrast showing diffuse leptomeningeal enhancement of the thoracic cord.

DISCUSSION

Neuroendocrine cells have been identified throughout the female genital tract, frequently affecting the uterus and ovaries. In 1972, Albores-Saavedra et al. first identified this pathology.[2,7] The mean overall survival of neuroendocrine cervical cancer is about 40 months, with a high rate of local and distant relapses.[27] The growth pattern and the high location of the cervix make early detection of these tumors difficult.[11,18] The Pap test has a poor diagnostic value in screening for small-cell neuroendocrine cancer.[10]

The most common primary treatment reported in the literature was radical surgery combined with chemotherapy, and platinum and etoposide were the most used.[20] Despite the multidisciplinary therapeutic approaches, the overall prognosis remains poor. Pure small-cell type histology is considered an independent prognostic factor.[8]

There is only one reported case of LMD in the context of a cervical high-grade neuroendocrine tumor.[22] There are no protocols for the management of LMD in patients with cervix neuroendocrine cancer. The European Association of Neuro-oncology European Society for Medical Oncology group determined certain criteria to diagnose LMD.[16] CSF cytology or biopsy can be diagnostic. If both clinical signs and MRI features are present, LMD diagnosis is probable, while in the presence of typical MRI findings without clinical signs, LMD is possible.[15,16] Kirkpatrick further described LMD either as nodular or diffuse.[12] Prabhu et al. reported a significant difference in overall survival in patients diagnosed with nodular LMD compared with diffuse LMD.[23] The radiosurgical treatment of patients with brain metastases may affect the incidence of LMD. Mahajan et al. reported a 28% rate of LMD in surgically resected brain metastases treated with adjuvant stereotactic radiosurgery[17], while Brown et al. found a rate of 7% at 1 year.[5] Our patient has the features of type IC, with a typical diagnostic cerebrospinal fluid cytology and a mixed pattern of leptomeningeal enhancement.

Given the dismal prognosis of LMD, the most common treatment is palliative radiation. Clinical trials involving LMD treatment include a combination of radiotherapy, systemic therapy, and intrathecal chemotherapy; however, studies have shown variable responses to treatment, making it difficult to use a general treatment protocol.[21] The poor permeability of chemotherapies limits the systemic treatment of LMD through the blood-brain barrier. A lack of clinical trials and evidence-based treatment of cervix neuroendocrine tumors constitutes a therapeutic challenge. Due to the scarcity of similar cases, the management was the same as small-cell neuroendocrine lung cancer and included surgery, chemoradiation, and systemic chemotherapy.

Whole brain radiotherapy dismantles the integrity of the blood-brain barrier and increases the cerebrospinal fluid (CSF) concentration of systemic therapies. Circulating tumor cells in the CSF favor the use of intrathecal therapy. The most used agents for intrathecal chemotherapy are methotrexate, thiotepa, and cytarabine.[14] They can be delivered through repeated lumbar punctures or ventricular devices. Topotecan used intrathecally for the treatment of LMD in patients with breast cancer showed promising results.[9] In this case report, the patient received WBRT without any neurological improvement, and the disease was so aggressive that the patient died before starting intrathecal therapy. Table 1 summarizes similar cases of neuroendocrine cervix tumors with LMD reported in the literature.

Table 1: Similar cases of uterine cervix cancer with LMD.

CONCLUSION

Clinical trials that involve small-cell neuroendocrine cell cancer (SCNECC) should be recruited to understand factors associated with LMD and determine the most efficient therapy. We report a rare case of a patient with SCNECC with brain metastasis and craniospinal LMD. The type of LMD in our case was mixed, which is different from the previously reported case.[22] Diagnosing and treating these cases is challenging, and the prognosis is disappointing.

Acknowledgment

I acknowledge the equal participation of all authors in the design and production of this manuscript.

Authors’ contributions

Dr. MA contributed to designing the idea and manuscript writing, Dr. AH contributed to the final review, and Dr. HM contributed to the editing. Dr. N contributed to the table design. Dr OA contributed to the final review.

Ethical approval

The research/study was approved by the Institutional Review Board at Cairo University Hospital, number CU1335, and dated January 10, 2024.

Declaration of patient consent

The authors certify that they have obtained appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

Disclaimer

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Journal or its management. The information contained in this article should not be considered to be medical advice; patients should consult their own physicians for advice as to their specific medical needs.

How to cite this article: Azab MA, Atallah O, El-Gohary N, Hazim A, Mostafa HA. Small-cell neuroendocrine carcinoma of the cervix with leptomeningeal spread: A rare coincidence report and literature review. Surg Neurol Int. 2024;15:310. doi: 10.25259/SNI_431_2024
==== Refs
REFERENCES

1 Ahn SJ Joo B Park M Park HH Suh SH Ahn SG Dural metastasis in breast cancer: MRI-based morphological subtypes and their clinical implications Cancer Res Treat 2024
2 Albores-Saavedra J Larraza O Poucell S Rodríguez Martínez HA Carcinoid of the uterine cervix: Additional observations on a new tumor entity Cancer 1976 38 2328 42 63316
3 Asensio N Luis A Costa I Oliveira J Vaz F Meningeal carcinomatosis and uterine carcinoma: Three different clinical settings and review of the literature Int J Gynecol Cancer 2009 19 168 72 19258961
4 Borm KJ Behzadi ST Hörner-Rieber J Krug D Baumann R Corradini S DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer Strahlenther Onkol 2024 200 259 75 38488902
5 Brown PD Ballman KV Cerhan JH Anderson SK Carrero XW Whitton AC Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC•3): A multicentre, randomized, controlled, phase 3 trial Lancet Oncol 2017 18 1049 60 28687377
6 Chilkulwar A Pottimutyapu R Wu F Padooru KR Pingali SR Kassem M Leptomeningeal carcinomatosis associated with papillary renal cell carcinoma Ecancermedicalscience 2014 8 468 25374616
7 Eichhorn JH Young RH Neuroendocrine tumors of the genital tract Am J Clin Pathol 2001 115 S94 112 11993694
8 Ishikawa M Kasamatsu T Tsuda H Fukunaga M Sakamoto A Kaku T Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study Gynecol Oncol 2018 148 139 46 29113721
9 Jaeckle KA Dixon JG Anderson SK Moreno-Aspitia A Colon-Otero G Hebenstreit K Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases Cancer Med 2020 9 7935 42 32885617
10 Kim MJ Kim NR Cho HY Lee SP Ha SY Differential diagnostic features of small cell carcinoma in the uterine cervix Diagn Cytopathol 2008 36 618 23 18677758
11 Kim Y Ha HJ Kim JS Chung JH Koh JS Park S Significance of cytologic smears in the diagnosis of small cell carcinoma of the uterine cervix Acta Cytol 2002 46 637 44 12146023
12 Kirkpatrick JP Classifying leptomeningeal disease: An essential element in managing advanced metastatic disease in the central nervous system Int J Radiat Oncol Biol Phys 2020 106 587 8 32014150
13 Klöppel G Neuroendocrine neoplasms: Dichotomy, origin and classifications Visc Med 2017 33 324 30 29177160
14 Kumar S Nair S Alexander M Carcinomatous meningitis occurring prior to a diagnosis of large cell neuroendocrine carcinoma of the uterine cervix J Postgrad Med 2004 50 311 2 15623983
15 Le Rhun E Devos P Weller J Seystahl K Mo F Compter A Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors Neuro Oncol 2021 23 1100 12 33367859
16 Le Rhun E Weller M Brandsma D Van den Bent M de Azambuja E Henriksson R EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours Ann Oncol 2017 28 Suppl 4 iv84 99 28881917
17 Mahajan A Ahmed S McAleer MF Weinberg JS Li J Brown P Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomized, controlled, phase 3 trial Lancet Oncol 2017 18 1040 8 28687375
18 Marlina YS Novirianthy R Beočanin A Palliative radiotherapy for leptomeningeal metastases after photon-based intensity-modulated radiotherapy in a nasopharyngeal cancer patient Narra J 2023 3 e266 38455636
19 Mizumatsu S Wakabayashi K Terashima Y Palliative treatment of leptomeningeal carcinomatosis from renal cell carcinoma with local cyberknife radiotherapy and systemic pazopanib therapy: A case report Cureus 2024 16 e54025 38476802
20 Muñoz N Bosch FX de Sanjosé S Herrero R Castellsagué X Shah KV Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 2003 348 518 27 12571259
21 Nayar G Ejikeme T Chongsathidkiet P Elsamadicy AA Blackwell KL Clarke JM Leptomeningeal disease: Current diagnostic and therapeutic strategies Oncotarget 2017 8 73312 28 29069871
22 Patterson JD Farach AM Singh M Britz GW Rostomily RC Leptomeningeal metastasis from neuroendocrine carcinoma of the cervix: Illustrative case J Neurosurg Case Lessons 2023 5 CASE22457 36718868
23 Prabhu RS Turner BE Asher AL Marcrom SR Fiveash JB Foreman PM A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases Neuro Oncol 2019 21 1049 59 30828727
24 Qin J Shahangian S Saraiya M Holt H Gagnon M Sawaya GF Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019 Gynecol Oncol 2021 163 378 84 34507826
25 Takayanagi A Florence TJ Hariri OR Armstrong A Yazdian P Sumida A Brain metastases from cervical cancer reduce longevity independent of overall tumor burden Surg Neurol Int 2019 10 176 31583173
26 Tan CY Yang QL Xu N Wang HJ Small cell neuroendocrine carcinoma of the cervix: An analysis for 5 cases and literature review Asian J Surg 2024 47 2508 9 38278733
27 Tempfer CB Tischoff I Dogan A Hilal Z Schultheis B Kern P Neuroendocrine carcinoma of the cervix: A systematic review of the literature BMC Cancer 2018 18 530 29728073
28 Pavithra V Shalini CN Priya S Rani U Rajendiran S Joseph LD Small cell neuroendocrine carcinoma of the cervix: A rare entity J Clin Diagn Res 2014 8 147 8 24701511
